Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02E60-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1087 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-1001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-1077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2011-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2013-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2013516456-A |
titleOfInvention |
Compositions and methods for treating glioblastoma GBM |
abstract |
A method of treating malignant glioma in a subject is disclosed. This method (I) a first polynucleotide sequence encoding a Fas chimera (Fas-c) comprising SEQ ID NOs: 2 and 3; and (ii) a first encoding an endothelial cell specific promoter or a periendothelial cell specific promoter. Administering to the subject a therapeutically effective amount of a viral vector comprising a second polynucleotide sequence. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102452370-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180124976-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11439612-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019509349-A |
priorityDate |
2010-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |